Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larisa Reyderman

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Journal of Clinical Pharmacology|April 29, 2014
Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanesOneeb Majid, Anubha Gupta, Larisa Reyderman, et al.
Current Medical Research and Opinion|September 24, 2004
Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteersLarisa Reyderman, Teddy Kosoglou, Tanya Boutros, et al.
Current Medical Research and Opinion|August 9, 2005
The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibeLarisa Reyderman, Teddy Kosoglou, David L Cutler, et al.
Journal of Clinical Pharmacology|December 16, 2022
Exposure-Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of InsomniaBojan Lalovic, Ishani Savant Landry, Margaret Moline, et al.
Epilepsy & Behavior : E&B|May 10, 2021
Use of extended-release and immediate-release anti-seizure medications with a long half-life to improve adherence in epilepsy: A guide for cliniciansBarry E Gidal, Jim Ferry, Larisa Reyderman, et al.
Clinical Pharmacokinetics|August 10, 2002
Lack of clinically relevant interaction between desloratadine and erythromycinChristopher Banfield, Thomas Hunt, Larisa Reyderman, et al.
Clinical Pharmacology in Drug Development|May 21, 2022
Intravenous Perampanel as an Interchangeable Alternative to Oral Perampanel: A Randomized, Crossover, Phase I Pharmacokinetic and Safety StudyZiad Hussein, Oneeb Majid, Peter Boyd, et al.
Pharmacology Research & Perspectives|March 10, 2021
Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexantIshani Landry, Jagadeesh Aluri, Nancy Hall, et al.
Pharmacology Research & Perspectives|November 2, 2020
Effect of gastric acid-reducing agents on the pharmacokinetics and efficacy of lemborexantIshani Landry, Jagadeesh Aluri, Nancy Hall, et al.
Pharmacology Research & Perspectives|April 6, 2021
Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexantSatish Dayal, Jagadeesh Aluri, Nancy Hall, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Journal of Clinical Pharmacology|April 29, 2014
Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanesOneeb Majid, Anubha Gupta, Larisa Reyderman, et al.
Current Medical Research and Opinion|September 24, 2004
Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteersLarisa Reyderman, Teddy Kosoglou, Tanya Boutros, et al.
Current Medical Research and Opinion|August 9, 2005
The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibeLarisa Reyderman, Teddy Kosoglou, David L Cutler, et al.
Journal of Clinical Pharmacology|December 16, 2022
Exposure-Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of InsomniaBojan Lalovic, Ishani Savant Landry, Margaret Moline, et al.
Epilepsy & Behavior : E&B|May 10, 2021
Use of extended-release and immediate-release anti-seizure medications with a long half-life to improve adherence in epilepsy: A guide for cliniciansBarry E Gidal, Jim Ferry, Larisa Reyderman, et al.
Clinical Pharmacokinetics|August 10, 2002
Lack of clinically relevant interaction between desloratadine and erythromycinChristopher Banfield, Thomas Hunt, Larisa Reyderman, et al.
Clinical Pharmacology in Drug Development|May 21, 2022
Intravenous Perampanel as an Interchangeable Alternative to Oral Perampanel: A Randomized, Crossover, Phase I Pharmacokinetic and Safety StudyZiad Hussein, Oneeb Majid, Peter Boyd, et al.
Pharmacology Research & Perspectives|March 10, 2021
Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexantIshani Landry, Jagadeesh Aluri, Nancy Hall, et al.
Pharmacology Research & Perspectives|November 2, 2020
Effect of gastric acid-reducing agents on the pharmacokinetics and efficacy of lemborexantIshani Landry, Jagadeesh Aluri, Nancy Hall, et al.
Pharmacology Research & Perspectives|April 6, 2021
Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexantSatish Dayal, Jagadeesh Aluri, Nancy Hall, et al.
Pageof 7